FDA Clearance Tracker · K230796
Sparrow Ascent
Last checked: Nov 19, 2026Latest source record: Jun 20, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Jun 20, 2023
Substantially Equivalent
Time to decision
90 days
Received Mar 22, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K230796
- Device name
- Sparrow Ascent
- Applicant
- Spark Biomedical, Inc.
- Applicant location
- Dallas, TX
- Received
- Mar 22, 2023
- Decided
- Jun 20, 2023
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device class
- Class II
- Regulation
- 21 CFR 882.5896
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code PZR. The earliest in FDA's data is DEN170018, decided Nov 15, 2017.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K230796
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Spark Biomedical, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Sparrow Ascent510(k)
K251246 · Decided Aug 25, 2025 · 125 days after receipt
Device type: Percutaneous Nerve Stimulator For Opioid Withdrawal (PZR) · Neurology & Neurosurgery
- Sparrow Therapy System510(k)
K201873 · Decided Jan 2, 2021 · 179 days after receipt
Device type: Percutaneous Nerve Stimulator For Opioid Withdrawal (PZR) · Neurology & Neurosurgery
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.